Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Free Cash Flow (2020 - 2025)

Rani Therapeutics Holdings has reported Free Cash Flow over the past 6 years, most recently at $308000.0 for Q4 2025.

  • Quarterly results put Free Cash Flow at $308000.0 for Q4 2025, up 103.55% from a year ago — trailing twelve months through Dec 2025 was -$18.8 million (up 47.47% YoY), and the annual figure for FY2025 was -$18.8 million, up 47.47%.
  • Free Cash Flow for Q4 2025 was $308000.0 at Rani Therapeutics Holdings, up from -$5.1 million in the prior quarter.
  • Over the last five years, Free Cash Flow for RANI hit a ceiling of $308000.0 in Q4 2025 and a floor of -$15.3 million in Q3 2023.
  • Median Free Cash Flow over the past 5 years was -$9.5 million (2022), compared with a mean of -$9.3 million.
  • Biggest five-year swings in Free Cash Flow: crashed 2606.62% in 2021 and later soared 103.55% in 2025.
  • Rani Therapeutics Holdings' Free Cash Flow stood at -$11.4 million in 2021, then fell by 28.81% to -$14.6 million in 2022, then rose by 13.58% to -$12.6 million in 2023, then surged by 31.31% to -$8.7 million in 2024, then soared by 103.55% to $308000.0 in 2025.
  • The last three reported values for Free Cash Flow were $308000.0 (Q4 2025), -$5.1 million (Q3 2025), and -$5.9 million (Q2 2025) per Business Quant data.